| Market Capitalization (Millions $) |
1 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
10 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-6 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
0 |
180 Life Sciences Corp
180 Life Sciences Corp is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of inflammatory disorders, fibrosis, and pain. The company utilizes its proprietary platform technology to identify and target key biological pathways involved in these conditions.
180 Life Sciences Corp aims to develop therapies that can provide much-needed relief to patients suffering from chronic inflammatory diseases such as fibrosis, arthritis, and multiple sclerosis. The company's approach involves utilizing anti-TNF therapies to target the TNF-alpha receptor, a key mediator of inflammation.
The company also seeks to address the high unmet medical need for non-opioid pain relief options by developing therapies that target the TRPV1 receptor, which plays a crucial role in pain signaling. These therapies have the potential to provide effective pain management without the risk of addiction associated with opioid medications.
180 Life Sciences Corp's pipeline includes several investigational drug candidates that have shown promising results in preclinical and early clinical studies. The company is focused on advancing these candidates through further clinical development and regulatory approval processes.
Overall, 180 Life Sciences Corp is dedicated to improving the lives of patients suffering from inflammatory disorders, fibrosis, and pain by developing innovative and effective therapies.
Company Address: 3000 El Camino Real Bldg. 4 Palo Alto 94306 CA
Company Phone Number: 507-0669 Stock Exchange / Ticker: NASDAQ ATNF
|
2.4% 